The current status of the problem with systemic lupus erythematosus in Kazakhstan

Objective: to analyze the provision of medical, including rheumatology, care in Kazakhstan, to study the incidence of systemic lupus erythematosus (SLE), and to develop a registry of patients with this condition.

Material and methods. The investigators analyzed the guidelines for the organization of medical, including rheumatology, care in the republic and the official statistical materials of the Ministry of Health of the Republic of Kazakhstan in the period 2012 to 2017. Articles were searched to select activity indices, organ damages and to assess the quality of life and treatment programs in order to create a registry of patients with SLE.

Results and discussion. The paper presents the basic principles of providing medical, including rheumatology, care in the republic. It gives data on the issues of providing SLE patients with medicines in outpatient and inpatient settings. It also analyzes trends in the incidence of SLE in the population of Kazakhstan in 2012 to 2017. There were 4,448 SLE patients, including 3,986 women; a comparative analysis of indicators demonstrated a 62.8% increase in the incidence of SLE from 2012 to 2017. The purpose and objectives of the registry of patients with SLE were substantiated.

Conclusion. An analysis of morbidity rates suggests that SLE remains to be significant in the republic. The incidence of SLE has been noted to increase in the period from 2012 to 2017; there is a female preponderance (89.6%). The application of the SLE registry in clinical practice will be able to improve the diagnosis of the disease in the early stage and to prevent possible complications. 

1. Nasonov EL, editor. Rossyskiye klinicheskiye rekomendatsii. Revmatologiya [Russian clinical guidelines. Rheumatology]. Moscow: GEOTAR-Media; 2019. P. 113-36 (In Russ.).

2. Pyle К, Kennedy L. Diagnostika i lechenie v revmatologii. Problemnyy podkhod [Diagnosis and treatment in rheumatology. The Problematic Approach]. Transl. from English under the editorship of Shostak NA. Moscow: GEOTAR-Media; 2011. P. 143-60 (In Russ.).

3. Klippel JH, Stone JH, Crofford LJ, White PH, editors. Revmaticheskie zabolevaniya. V 3 t. T. III. Zabolevaniya myagkikh tkaney: Rukovodstvo [Rheumatic diseases. In 3 vol. Vol. III. Soft Tissue Disease: A Guide]. Transl. frоm the English under the editorship of Nasonov EL, Nasonova VА, Olyunin YuA. Moscow: GEOTAR-Media; 2011. P. 21-84 (In Russ.).

4. Bengtsson AA, Rönnblom L. Systemic Lupus erythematosus: still a chellenge for physicians. Intern Med. 2017 Jan;281(1): 52-64. doi: 10.1111/joim.12529

5. Sacks JJ, Helmick CG, Langmaid G, Sniezek JE. Trends in deaths from systemic lupus erythematosus – United States, 1979–1998. MMWR Morbid Mortal Wkly Rep. 2002;51(17):371-4.

6. Bernatsky S, Clarke A, Gladman DD, et al. Mortality related to cerebrovascular disease in systemic lupus erythematosus. Lupus. 2006;15(12):835-9. doi: 10.1177/0961203 306073133

7. Centers for Disease Control and Prevention, National Center for Health Statistics. Compressed Mortality File 1999–2016 on CDC WONDER Online Database. Available at: http://wonder.cdc.gov/cmf-icd10.html (accessed June 1, 2018).

8. Ocampo-Piraquive V, Nieto-Aristizabal I, Canas CA, Tobon GJ. Mortality in systemic lupus erythematosus: causes, predictors and interventions. Expert Rev Clin Immunol. 2018 Dec;14(12):1043-53. doi: 10.1080/1744666X.2018.1538789

9. Yen EY, Shaheen M, Woo JMP, et al. Lupus mortality rates remain high, despite improving trends. Ann Intern Med. 2017; 167(11):777-85. doi: 10.7326/M17-0102

10. Watson P, Brennan A, Birch H, et al. An integrated extrapolation of long-term outcomes in systemic lupus erythematosus: analysis and simulation of the Hopkins lupus cohort. Rheumatology (Oxford). 2015 Apr; 54(4):623-32. doi: 10.1093/rheumatology/ keu375

11. Albrecht K, Huscher D, Richter J, et al. Changes in referral, treatment and outcomes in patients with systemic lupus erythematosus in Germany in the 1990s and the 2000s. Lupus Sci Med. 2014;1:e000059. doi: 10.1136/lupus-2014-000059

12. Yee CS, Su L, Toescu V, et al. Birmingham SLE cohort: outcomes of a large inception cohort followed for up to 21 years. Rheumatology (Oxford). 2015 May;54(5): 836-43. doi: 10.1093/rheumatology/keu412

13. Lerang K, Gilboe IM, Steinar Thelle D, Gran JT. Mortality and years of potential life loss in systemic lupus erythematosus: a population-based cohort study. Lupus. 2014 Dec; 23(14):1546-52. doi: 10.1177/0961203314 551083

14. Fernandez-Nebro A, Rua-Figueroa I, Lopez-Longo FJ, et al. Cardiovascular Events in Systemic Lupus Erythematosus. A Nationwide Study in Spain From the RELESSER Registry. Medicine (Baltimore). 2015 Jul;94(29):e1183. doi: 10.1097/MD.0000000000001183

15. Van Vollenhoven RF, Mosca M, Bertsias G, et al. Treat-to-target in systemic lupus erythematosus: recommendations from an international task force. Ann Rheum Dis. 2014 Jun; 73(6):958-67. doi: 10.1136/annrheumdis2013-205139

16. Soloviev SK, Aseeva EA, Popkova TV, et al. Treat-to-target SLE recommendations from the international task force and russian experts’ commentaries. NauchnoPrakticheskaya Revmatologiya = Rheumatology Science and Practice. 2015;53(1):9-16. doi: 10.14412/1995-4484-2015-9-16 (In Russ.).

17. Shamliyan TA, Dospinescu P. Additional Improvements in Clinical Response From Adjuvant Biologic Response Modifiers in Adults With Moderate to Severe Systemic Lupus Erythematosus Despite Immunosuppressive Agents: A Systematic Review and Meta-analysis. Clin Ther. 2017 Jul;39(7):1479-506.e45. doi: 10.1016/j.clinthera.2017.05.359

18. Tesar V, Hruskova Z. Belimumab in the management of systemic lupus erythematosus – an update. Еxpert Opin Biol Ther. 2017 Jul;17(7):901-8. doi: 10.1080/14712598.2017.1324846

19. Guerreiro CS, Isenberg DA. Belimumab in systemic lupus erythematosus (SLE): evidence-to-date and clinical usefulness. Ther Adv Musculoskelet Dis. 2017 Mar;9(3):75-85. doi: 10.1177/1759720X17690474

20. Aseeva EA, Soloviev SK, Mesnyankina AA, et al. Results of an observational prospective study of the efficacy and safety of belimumab (Benlysta®) in systemic lupus erythematosus in real clinical practice. NauchnoPrakticheskaya Revmatologiya = Rheumatology Science and Practice. 2016;54(1):31-7. doi: 10.14412/1995-4484-2016-31-37 (In Russ.).

21. Mesnyankina AA, Solovyev SK, Aseeva EA, Nasonov EL. The efficiency of biological therapy and the features of humoral immunity in patients with systemic lupus erythematosus. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2018; 56(3):302-9. doi: 10.14412/1995-4484-2018-302-309 (In Russ.).

22. Mosca M, Tani C, Aringer M, et al. European League Against Rheumatism recommendations for monitoring patients with systemic lupus erythematosus in clinical practice and in observational studies. Ann Rheum Dis. 2010 Jul;69(7):1269-74. doi: 10.1136/ard.2009.117200

23. Aringer M, Costenbader K, Daikh D, et al. 2019 European League Against Rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus. Ann Rheum Dis. 2019;0:1151-9. doi: 10.1136/annrheumdis2018-214819

24. Fanouriakis A, Kostopoulou M, Alunno A, et al. 2019 update of the EULAR recommendations for management of systemic lupus erythematosus. Ann Rheum Dis. 2019;78:736- 45. doi: 10.1136/annrheumdis-2019-215089

25. Aseeva EA, Solovyev SK, Klyukvina NG, et al. Irreversible organ damages in a cohort of patients with systemic lupus erythematosus (RENAISSANCE). Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2016;54(4):404-11. doi: 10.14412/1995-4484-2016-404-411 (In Russ.).

26. Petri M, Orbai M, Alarcon G, et al. Derivation and validation of the Systemic Lupus International Collaborating Clinics. Classification Criteria for systemic lupus erythematosus. Arthritis Rheum. 2012;64(8): 2677-86. doi: 10.1002/art.34473

27. Gladman DD, Urowitz MB, Goldsmith CH, et al. The reliability of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology damage index in patients with systemic lupus erythematosus. Arthritis Rheum. 1997;40(5): 809-13. doi: 10.1002/art.1780400506

28. Gladman DD, Ibanez D, Urowitz MB. Systemic lupus erythematosus disease activity index 2000. J Rheumatol. 2002;29:288-91.

29. Gladman DD, Goldsmith CH, Urowitz MB, et al. The Systemic Lupus International Collaborating Clinics/American College of Rheumatology (SLICC/ACR) damage index for systemic lupus erythematosus international comparison. J Rheumatol. 2000;27(2):373-6.

30. Rahman A, Gladman DD, Isenberg DA, et al. Early damage as measured by the SLICC/ACR Damage Index is a predictor of mortality in SLE. Lupus. 2001;10:93-6. doi: 10.1191/096120301670679959

31. McElhone K, Abbott J, Gray J, et al. Patient perspective of systemic lupus erythematosus in relation to healthrelated quality of life concepts: a qualitative study. Lupus. 2010; 19:1640-7. doi: 10.1177/0961203310378668

32. Mcelhone K, Abbott J, Shelmardine J, et al. Development and validation of a disease-specific health-related quality of life measure, the LupusQol, for adults with systemic lupus erythematosus. Arthritis Rheum. 2007;57(6):972-9. doi: 10.1002/art.22881

33. Abisheva ST, Sarmanova AA. Quality-of-life issues in the comprehensive examination of patients with systemic lupus. NauchnoPrakticheskaya Revmatologiya = Rheumatology Science and Practice. 2014;52(4):445-50. doi: 10.14412/1995-4484-2014-445-450 (In Russ.).

34. Nasonov EL, editor. Klinicheskiye rekomendatsii.Revmatologiya [Rheumatology: clinical recomemmendations. Quality of life of patients SF-36 v.1tm]. 2nd ed. Moscow: GEOTAR-Media; 2010. P. 710-25 (In Russ.).

35. Aseeva EA, Vorobyeva LD, Solovyev SK, et al. The psychometric properties of a Russian version of the disease-specific LupusQol questionnaire assessing the healthrelated quality of life in patients with systemic lupus erythematosus. NauchnoPrakticheskaya Revmatologiya = Rheumatology Science and Practice. 2018; 56(2):164-72. doi: 10.14412/1995-4484-2018-164-172 (In Russ.).

36. Zdorov'e naseleniya Respubliki Kazakhstan i deyatel'nost' organizatsiy zdravookhraneniya v 2012 godu: Stat. sb. [The health of the population of the Republic of Kazakhstan and the activities of health organizations in 2012. Statistical compilation]. Astana; 2013. P. 27-85. Available from: http://www.enbek.gov.kz/sites/default/files/2012 (In Russ.).

37. Zdorov'e naseleniya Respubliki Kazakhstan i deyatel'nost' organizatsiy zdravookhraneniya v 2013 godu: Stat. sb. [The health of the population of the Republic of Kazakhstan and the activities of health organizations in 2013. Statistical compilation]. Astana; 2014. P. 35-9. Available from: http://www.enbek.gov.kz/sites/default/files/2014 (In Russ.).

38. Zdorov'e naseleniya Respubliki Kazakhstan i deyatel'nost' organizatsiy zdravookhraneniya v 2014 godu: Stat. sb. [Population health of the Republic of Kazakhstan and the activities of health organizations in 2014. Statistical compilation]. Astana; 2015. P. 35-9. Available from: http://www.mz.gov.kz/sites/default/files/pages/sbornik_2014 (In Russ.).

39. Zdorov'e naseleniya Respubliki Kazakhstan i deyatel'nost' organizatsiy zdravookhraneniya v 2015 godu: Stat. sb. [The health of the population of the Republic of Kazakhstan and the activities of health organizations in 2015. Statistical compilation Astana; 2016. P. 35-42. Available from: http://www.mz.gov.kz/sites/default/files/pages/sbornik_za_2015_dlya_razmeshcheniya_na_sayte (In Russ.).

40. Zdorov'e naseleniya Respubliki Kazakhstan i deyatel'nost' organizatsiy zdravookhraneniya v 2015 godu: Stat. sb. [Health of the population of the Republic of Kazakhstan and the activities of health organizations in 2016. Statistical compilation]. Astana; 2017. P. 35-9. Available from: http://www.mz.gov.kz/sites/default/files/pages/sbornik_2017 (In Russ.).

41. Form 12. Report on the number of diseases registered in the service area of the medical organization and contingents of patients under medical supervision. 2012–2016. Available from: http://www.medinfo.kz (In Russ.).

42. Decree of the President of the Republic of Kazakhstan. On approval of the State program for the development of health care of the Republic of Kazakhstan «Salamatty Kazakhstan» for 2016–2019 (with amendments and additions as of 15.01.2016) (In Russ.).

43. Decree of the President of the Republic of Kazakhstan. On approval of the State program for the development of health care of the Republic of Kazakhstan «Salamatty Kazakhstan» for 2011–2015.

44. The state program «Information Kazakhstan – 2020» approved by Decree of the President of the Republic of Kazakhstan dated January 8, 2013 No. 464 (In Russ.).

45. On approval of the Standard for the organization of rheumatological care in the Republic of Kazakhstan. Order of the Minister of Health and Social Development of the Republic of Kazakhstan dated February 18, 2016 No. 126. Registered with the Ministry of Justice of the Republic of Kazakhstan on March 15, 2016 No. 13474 (In Russ.).

46. A brief description of the information system. Available from:https://ezdrav.kz/index.php/ru/forusers/sistemy-kratkoeopisanie.htm (In Russ.).

47. The order of the Ministry of Health and Social Development of the Republic of Kazakhstan No. 367 of May 21, 2015 «On approval of the list of socially significant diseases and diseases that are dangerous to others». Available at: http://adilet.zan.kz/rus/origins/V1500011512 (In Russ.).

48. Jonson AE, Gordon C, Palmer RG, Bacon PA. The prevalence and incidence of systemic lupus erythematosus in Birmingham, England. Relationship to ethnicity and country of birth. Arthritis Rheum. 1995 Apr;38(4):551-8. doi: 10.1002/art.1780380415

49. Osio-Salido E, Manapat-Reyes H. Epidemiology of systemic lupus erythematosus in Asia. Lupus. 2010 Oct;19(12):1365-73. doi: 10.1177/0961203310374305